April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Contrast sensitivity evaluation in high-risk treatment-naïve proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal Ranibizumab.
Author Affiliations & Notes
  • Daniel Araujo Ferraz
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Lisa Vasquez
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Augusto Motta
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Rony C Preti
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Raafay Sophie
    Ophthalmology, wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Millena Gomes Bittencourt
    Ophthalmology, wilmer Eye Institute, Johns Hopkins University, Baltimore, MD
  • Mario L R Monteiro
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Walter Y Takahashi
    Ophthalmology, University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships Daniel Ferraz, None; Lisa Vasquez, None; Augusto Motta, None; Rony Preti, None; Raafay Sophie, None; Millena Bittencourt, None; Mario Monteiro, None; Walter Takahashi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4414. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniel Araujo Ferraz, Lisa Vasquez, Augusto Motta, Rony C Preti, Raafay Sophie, Millena Gomes Bittencourt, Mario L R Monteiro, Walter Y Takahashi; Contrast sensitivity evaluation in high-risk treatment-naïve proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal Ranibizumab.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4414.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effects on contrast sensitivity (cs) measurements of panretinal photocoagulation (prp) associated with intravitreal ranibizumab (rbz) injections versus prp alone in non-high risk treatment-naïve proliferative diabetic retinopathy (pdr) eyes.

Methods: Fifty eyes of 25 patients with bilateral pdr were randomised to two groups: one randomly selected eye underwent prp and rbz injections (study group, sg) and the other prp alone (control group, cg). All eyes were treated with prp administered in three sessions according to etdrs guidelines. Intravitreal rbz injections (sg) or sham injections (cg) were given at weeks 1 and 4. Cs measurements were performed under photopic conditions (85cd/m2) with the vcts 6500 chart (vistech consultants incorporation, dayton, ohio, usa) positioned 3 m away, allowing for evaluation of five spatial frequencies with sine wave grating charts: 1.5, 3.0, 6.0, 12.0 and 18.0 cycles per degree (cpd).main outcome measures: mean change in cs threshold scores amongst and within groups, from baseline to 1, 3 and 6 months.

Results: Forty eyes (22 sg and 18 cg) were evaluated, as they had no hemorrhage at any visit. Mean cs threshold in between the two groups showed no significant differences (p>0.05) except at month 1 at 3.0 cpd. Cg had significant worsening (p<0.05) of cs at 3.0 cpd after 1 month. Sg had no significant change. A trend towards worsening for the cg and improvement for the sg at 1.5 and 18.0 cpd, worsening at month 1 but improvement at months 3 and 6 in cg but improvement from month 1 onwards in sg at 6.0 and 12.0, and worsening in both groups at 3.0 cpd was noted.

Conclusions: In eyes with non-high risk-pdr, prp treatment is associated with early worsening of cs while adjuvant use of rbz prevents such deterioration. Cs evaluation seems to support the adjuvant use of rbz when using prp for the treatment of pdr.

Keywords: 499 diabetic retinopathy • 478 contrast sensitivity • 578 laser  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×